DE1906551B2 - 2-alkoxy-3,5-dihalophenyl dialkylaminoalkyl ethers - Google Patents
2-alkoxy-3,5-dihalophenyl dialkylaminoalkyl ethersInfo
- Publication number
- DE1906551B2 DE1906551B2 DE1906551A DE1906551A DE1906551B2 DE 1906551 B2 DE1906551 B2 DE 1906551B2 DE 1906551 A DE1906551 A DE 1906551A DE 1906551 A DE1906551 A DE 1906551A DE 1906551 B2 DE1906551 B2 DE 1906551B2
- Authority
- DE
- Germany
- Prior art keywords
- solution
- added
- alkoxy
- methoxy
- dichlorobenzene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Insulating Bodies (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
R2 ίο fügt 2 Liter Wasser hinzu, wobei man ständig weiter-R 2 ίο add 2 liters of water, continually
OR3 rührt. Die chlorierte Verbindung kristalliert aus. SieOR 3 stirs. The chlorinated compound crystallizes out. she
_J IL γ ™*ά abgesaugt, gewaschen und mit 125 ml 30%iger_J IL γ ™ * ά suctioned off, washed and with 125 ml 30% iger
—"\/~ Natronlauge deacetyliert. Das Produkt wird destilliert- "\ / ~ Sodium hydroxide solution deacetylated. The product is distilled
und dann aus Petroläther umkristallisiert. Man erhält in der η und m 0, 1 oder 2, 15 66 g 3,5-Dichlorguajakol (Schmp. 62 bis 63° C, Aus-and then recrystallized from petroleum ether. In the η and m 0, 1 or 2, 15 66 g of 3,5-dichloroguajakol (melting point 62 to 63 ° C, ex
R1, R* und Ra die Methyl-, Äthyl- oder Propyl- beute 68%).R 1 , R * and R a the methyl, ethyl or propyl booty 68%).
r^a^au» oder die M^l-, **■ ** B: r ^ a ^ au »or the M ^ l-, ** ■ ** B:
oder Propylgruppe sowieor propyl group as well
X und Y Fluor-, Chlor- oder Bromatome bedeuten, *> 50 g 3,5-Dichlorguajakol (0,25 Mol) werden in eineX and Y mean fluorine, chlorine or bromine atoms, *> 50 g of 3,5-dichloroguajakol (0.25 mol) are poured into a
sowie deren Salze mit anorganischen oder orga- Natriumäthylatlösung gegeben, die aus 6 g Natriumand their salts with inorganic or organic sodium ethylate solution, which are made from 6 g of sodium
nischen Säuren. und 68 ml absolutem Alkohol hergestellt istniche acids. and 68 ml of absolute alcohol is made
2. Verfahren zur Herstellung der 2-Alkoxy- Man erhält eine rote Lösung, der man 39 g (0,26 Mol 3,5 - dihalogenphenyldialkylaminoalkyläther nach + 10% Überschuß) Diäthylaminoäthylchlorid hinzu-Anspruch 1, dadurch gekennzeichnet, daß man "5 fügt.2. Process for the preparation of the 2-alkoxy A red solution is obtained which contains 39 g (0.26 mol 3,5 - dihalogenphenyldialkylaminoalkyl ether after + 10% excess) diethylaminoethyl chloride added claim 1, characterized in that "5" is added.
jeweils in an sich bekannter Weise einen Brenz- Man erwärmt vorsichtig; die Lösung trübt sich undIn each case, in a manner known per se, a Brenz-Man is carefully warmed up; the solution becomes cloudy and
catechinmonoalkyläther acetyliert und halogeniert. Natriumchlorid fällt aus. Man erhitzt dann 7 Stundencatechol monoalkyl ethers acetylated and halogenated. Sodium chloride precipitates. The mixture is then heated for 7 hours
die so erhaltene Verbindung deacetyliert und mit lang unter Rückfluß. Anschließend kühlt man undthe compound thus obtained is deacetylated and refluxed with long. Then you cool and
einem entsprechenden Alkylaminoalkylchlorid um- fügt 300 ml Wasser und 25 ml konzentrierter Salzsäure setzt und gegebenenfails den entstandenen Äther 30 hinzu. Die wäßrige Lösung wird filtriert und über300 ml of water and 25 ml of concentrated hydrochloric acid are added to a corresponding alkylaminoalkyl chloride and if necessary add the resulting ether 30. The aqueous solution is filtered and poured over
mit Säuren in die Sake überführt. Aktivkohle geleitet. Die Base wird mit 40 ml Am-transferred into the sake with acids. Activated carbon passed. The base is mixed with 40 ml of am-
3. Arzneimittel, enthaltend die 2-Alkoxy-3,5-di- moniak ausgefällt_ und mit Äther extrahiert. Nach halogenphenyldialkylaminoalkyläther nach An- Destillation des Äthers erhält man 51 g (Ausbeute Spruch 1 als Wirkstoff. 72%)l-Diäthylaminoäthoxy-2-methoxy-3,5-dichlor-3. Medicinal products containing the 2-alkoxy-3,5-di- monia precipitated and extracted with ether. To Halophenyldialkylaminoalkyl ether after distillation of the ether gives 51 g (yield Proverb 1 as an active ingredient. 72%) l-diethylaminoethoxy-2-methoxy-3,5-dichloro
35 benzol (Sdp. 7 165—1660C).35 benzene (bp. 7165-166 0 C).
Stufe C: Hydrochlorid des l-Diäthylaminoäthoxy-Stage C: L-diethylaminoethoxy hydrochloride
2-methoxy-3,5-dichlorbenzols2-methoxy-3,5-dichlorobenzene
Die Erfindung betrifft den in den Ansprüchen ge- Man löst die im vorhergehenden VerfahrensschrittThe invention relates to the one achieved in the claims in the preceding method step
kennzeichneten Gegenstand. 40 erhaltene Base in 100 ml Aceton und fügt eine Lö-marked object. 40 base obtained in 100 ml of acetone and adds a solution
Die Verbindungen der Erfindung weisen wertvolle sung von 6,35 g trockener Salzsäure in 20 ml Aceton pharmakologische Eigenschaften, insbesondere als hinzu. Das Hydrochlorid des 1-Diäthylaminoäthoxy-Spasmogene, auf. Im Tierversuch konnte ihre Über- 2-methoxy-3,5-dichlorbenzols fällt aus, wird abgelegenheit gegenüber der Vergleichsverbindung Acetyl- saugt, mit Aceton gewaschen und dann getrocknet, cholin gezeigt werden (s. Versuchsberichte). 45 Man erhält 51 g des Produktes (Schmp. 132 bis 1340C).The compounds of the invention have valuable solution of 6.35 g of dry hydrochloric acid in 20 ml of acetone pharmacological properties, especially as an additive. The hydrochloride of 1-diethylaminoethoxy-spasmogenic. In animal experiments, their excess 2-methoxy-3,5-dichlorobenzene precipitates, is removed from the comparison compound acetyl suction, washed with acetone and then dried, choline can be shown (see test reports). 45 is obtained 51 g of product (mp. 132 to 134 0 C).
Die Verbindungen der Erfindung können hergestelltThe compounds of the invention can be prepared
werden, indem man jeweils in an sich bekannter Ana|yse by using an ana | y se
Weise einen Brenzcatechinmonoalkyläther acetyliert Berechnet %: C 47,49, H 6,09, Cl 32,42, N 4,26;A catechol monoalkyl ether is acetylated. Calculated%: C 47.49, H 6.09, Cl 32.42, N 4.26;
und halogeniert, die so erhaltene Verbindung de- gefunden %: C 47,31. H 6,14, Cl 32,24, N 4,18.
acetyliert und mit einem entsprechenden Alkylamino- 50and halogenated, the compound thus obtained was found%: C 47.31. H 6.14, Cl 32.24, N 4.18.
acetylated and with a corresponding alkylamino 50
alkylchlorid umsetzt und gegebenenfalls den gebil- Beispiel 2reacts alkyl chloride and, if necessary, the formed Example 2
deten Äther mit Säuren in die Salze überführt. Hydrochlorid des 1-Dimethylaminopropoxy-deten ether converted into salts with acids. 1-dimethylaminopropoxy hydrochloride
Die Herstellung einiger erfindungsgemäßer Verbin- 2-methoxy-3,5-dichlorbenzols
düngen wird in den folgenden AusführungsbeispielenThe preparation of some compounds according to the invention 2-methoxy-3,5-dichlorobenzene
fertilize is used in the following examples
näher erläutert. 55 Die Stufe A wird wie bei Beispiel 1 beschriebenexplained in more detail. 55 Stage A is described as in Example 1
Beispiel 1 durchgeführt.Example 1 carried out.
TT ,,,..,,_.„,,.., „ , Stufe B: l-Dimethylaminopropoxy-2-methoxy- TT ,,, .. ,, _. ",, ..,", Level B: l-dimethylaminopropoxy-2-methoxy-
Hydrochlond des l-Diathylammoathoxy-2-methoxy- 3 5-dichlorbenzol1-Diethylammoathoxy-2-methoxy-3 5-dichlorobenzene hydrochloride
3,5-dichlorbenzols3,5-dichlorobenzene
„..,._... . , , 60 63 g 3,5-Dichlorguajakol (0,32 Mol) gibt man in".., ._.... ,, 60 63 g of 3,5-dichloroguajakol (0.32 mol) are added to
Stufe A: 3,5-Dichlorguajakol eine Natriumäthylatlösung, die man aus 7,5g Na-Stage A: 3,5-Dichlorguajakol a sodium ethylate solution, which is made from 7.5g Na-
In einem 250-ml-Kolben mit Rücklaufkühler ace- trium und 100 ml Äthylalkohol erhält. Man fügt 44 g tyliert man 62 g Guajakol (0,5 Mol) mit Essigsäure- (0,326 Mol + 10% Überschuß) 1-Dimethylamino* anhydrid in Gegenwart einiger Tropfen konzentrierter 3-chlorpropan hinzu und erhitzt das erhaltene GeSchwefelsäure. Wenn die Reaktion abgeschlossen ist, 65 misch 6 Stunden lang unter Rückfluß. Man beobachtet neutralisiert man die Schwefelsäure mit Natriumacetat. eine Fällung von Natriumchlorid. Man kühlt und Nach Abkühlung der Lösung folgt die Chlorierung des extrahiert mit 300 ml Wasser und 30 ml konzentriertet Guajakolacetats. Salzsäure. Die wäßrige Lösung wird über AktivkohleIn a 250 ml flask with a reflux condenser, ace- trium and 100 ml ethyl alcohol are obtained. 44 g are added 62 g of guaiacol (0.5 mol) are tylated with acetic acid (0.326 mol + 10% excess) 1-dimethylamino * anhydride is added in the presence of a few drops of concentrated 3-chloropropane and the resulting sulfuric acid is heated. When the reaction is complete, mix at reflux for 6 hours. One observes the sulfuric acid is neutralized with sodium acetate. a precipitation of sodium chloride. One cools and After cooling the solution, the chlorination of the extracted with 300 ml of water and concentrated 30 ml follows Guaiacol acetate. Hydrochloric acid. The aqueous solution is poured over activated charcoal
3 43 4
geleitet. Die erhaltene Base wird durch Zusatz von Man läßt wasserfreie Salzsäure in die gleichedirected. The base obtained is added by adding anhydrous hydrochloric acid to the same
dampft diesen und destilliert den Rückstand. Base bis zum Farbumschlag von Methylrot Dasevaporate this and distill the residue. Base until the color changes from methyl red Das
propoxy^-methoxyO.S-dichlorbenzol (Sdp. 25 190 bis 5 waschen und dann an der Luft sowie im Wärme-propoxy ^ -methoxyO.S-dichlorobenzene (bp 25 190 to 5 wash and then in the air and in the heat
195°Q. schrank bei 300C getrocknet. Es wird mehrmals aus195 ° Q. cabinet dried at 30 0 C. It gets out several times
c. , ρ „ j ., .. . , _,. . , . Isopropanol umkristallisiert Man erhält 51 g 1-Di- c . , ρ "j., ... , _ ,. . ,. Isopropanol recrystallized. 51 g of 1-di-
propoxy^-methoxy-S.S-dichlorbenzols drochlorid (Schmp. 142°C; Ausbeute 48%).propoxy ^ -methoxy-S.S-dichlorobenzene hydrochloride (melting point 142 ° C; yield 48%).
7,85 g wasserfreie Salzsäure, die in 70 ml Aceton Berechnet %: C 49,05, H 6,42, Cl 31,09, N 4,09;7.85 g of anhydrous hydrochloric acid in 70 ml of acetone Calculated%: C 49.05, H 6.42, Cl 31.09, N 4.09;
gelöst ist, hinzu. Das Hydrochlorid des 1-Düaethyl- gefunden %: C 49,16, H 6,46, Cl 30,90, N 4,19. ammopropoxy-2-medu}xy-3,5-dichlorbeazols fällt aus.is resolved. The 1-diaethyl hydrochloride found%: C 49.16, H 6.46, Cl 30.90, N 4.19. ammopropoxy-2-medu} xy-3,5-dichlorobeazols precipitates.
l-Diäthylaminoisopropoxy^-methoxy-S.S-dichlor-Berechnet %: C 45,79, H 5,72, Cl 33,86, N 4,45; benzol-oxalat1-diethylaminoisopropoxy ^ -methoxy-S.S-dichloro-Calculated%: C 45.79, H 5.72, Cl 33.86, N 4.45; benzene oxalate
gefunden %: C 45,59, H 5,79, α 3j,72, N 4,39. _. o , . . . · w · D · · , 1 u u · 1,Found%: C 45.59, H 5.79, α 3j, 72, N 4.39. _. o,. . . W D , 1 uu 1,
' Die Stufe A wird wie bei Beispiel 1 beschriebenStage A is described as in Example 1
2-methoxy-3,5-dichIorbenzols 3,5-dichlorbenzol2-methoxy-3,5-dichlorobenzene 3,5-dichlorobenzene
durchgeführt 95 Natriumäthylat hinzugefügt, welches durch Auflösencarried out 95 sodium ethylate added, which by dissolving
„ . _ , _._ ... - , von 7,5 g Natrium in 100 ml Alkohol erhalten wird.". _, _._ ... -, is obtained from 7.5 g of sodium in 100 ml of alcohol.
3,5-dichlorbenzol + 10 % Oberschuß) jJ-Chlorpropyl -diäthylamin hinzu.3,5-dichlorobenzene + 10% excess) jJ-chloropropyl diethylamine added.
3,5-DichlorguajakoI (0,34 Mol) werden in eine Na- 30 triumchlorid ausfällt. Man extrahiert mit 300 ml3,5-DichlorguajakoI (0.34 mol) will precipitate into sodium chloride. Extract with 300 ml
itriumäthylatlösung gegeben, die aus 7 g Natrium und Wasser und 4,5 ml konzentrierter Salzsäure, nitriertitriumäthylatlösung given, which nitrated from 7 g of sodium and water and 4.5 ml of concentrated hydrochloric acid
130 ml absolutem Alkohol hergestellt ist. Zu der er- die Lösung und fügt 60 ml Ammoniak hinzu. Die aus-130 ml of absolute alcohol is produced. The solution is added to this and 60 ml of ammonia are added. From-
haltenen roten Lösung fügt man 55 g Diäthylamino- gefällte Base wird mit Äther extrahiert. Man dampftHolding the red solution, 55 g of diethylamino-precipitated base are added and the mixture is extracted with ether. One steams
propylchlorid (0,34 Mol + 10% Überschuß) hinzu. den Äther ab und destilliert den Rückstand.propyl chloride (0.34 mol + 10% excess) was added. the ether off and the residue is distilled.
sich die Lösung und Natriumchlorid fällt aus. Man aminoisopropoxy-3,5-dichlorbenzol (Sdp. 5 166 bisthe solution and sodium chloride precipitate. One aminoisopropoxy-3,5-dichlorobenzene (b.p. 5 166 bis
erhitzt dann 2 Stunden lang unter Rückfluß. 167° C).then refluxed for 2 hours. 167 ° C).
aus. Man dekantier? extrahiert mehrmals mit Me- StufeC: l-the end. Do you decant? extracted several times with Me- level C: l-
thylenchlorid und wäscht die organische Lösung mit 40ethylene chloride and washes the organic solution with 40
einer 4%igen Natriumhydroxidlösung sowie mit Die vorstehend erhaltene Base wird in 130 ml ab-a 4% sodium hydroxide solution and with The base obtained above is removed in 130 ml
stilliert das Lösungsmittel ab. Man erhält 96 g 1-Di- 21 g Oxalsäure in 40 ml Alkohol hinzu. Das Oxalatremoves the solvent. 96 g of 1-di- 21 g of oxalic acid in 40 ml of alcohol are obtained. The oxalate
äthylaminopropoxy^-methoxy-S.S-dichlorbenzoliAus- des l-Diäthylaminoisopropoxy^-methoxy-S.S-dichlor-äthylaminopropoxy ^ -methoxy-S.S-dichlorobenzoliAus- des l-diethylaminoisopropoxy ^ -methoxy-S.S-dichloro-
beute: 95%). 45 benzols fällt aus, wird abgesaugit, mit Alkohol ge-prey: 95%). 45 benzene precipitates, is sucked off, mixed with alcohol
o t π τ» j Li -λ j 1 η- L 1 · waschen und getrocknet (Schmp. 128°C).o t π τ »j Li -λ j 1 η- L 1 · wash and dry (melting point 128 ° C.).
2-methoxy-3,5-dichlorbenzols Analyse2-methoxy-3,5-dichlorobenzene analysis
wird in der doppelten Gewichtsmenge Aceton gelöst. 50 gefunden %: C 48,28, H 5,98, Cl 17,80, N 3,39.is dissolved in twice the amount by weight of acetone. 50 found%: C 48.28, H 5.98, Cl 17.80, N 3.39.
Claims (1)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR140294 | 1968-02-16 | ||
FR140294 | 1968-02-16 | ||
FR151632A FR7615M (en) | 1968-05-10 | 1968-05-10 | |
FR151632 | 1968-05-10 |
Publications (3)
Publication Number | Publication Date |
---|---|
DE1906551A1 DE1906551A1 (en) | 1969-08-21 |
DE1906551B2 true DE1906551B2 (en) | 1975-07-17 |
DE1906551C3 DE1906551C3 (en) | 1976-02-26 |
Family
ID=
Also Published As
Publication number | Publication date |
---|---|
ZM969A1 (en) | 1969-11-17 |
LU58009A1 (en) | 1969-09-18 |
YU33793B (en) | 1978-05-15 |
FI50789B (en) | 1976-03-31 |
IE32961B1 (en) | 1974-02-06 |
JPS4934669B1 (en) | 1974-09-17 |
MC809A1 (en) | 1970-07-30 |
SE367184B (en) | 1974-05-20 |
IL31594A (en) | 1973-02-28 |
BR6906462D0 (en) | 1973-01-16 |
ES363662A1 (en) | 1971-01-01 |
CH490328A (en) | 1970-05-15 |
NL6902401A (en) | 1969-08-19 |
CA928299A (en) | 1973-06-12 |
YU33269A (en) | 1977-10-31 |
BG15205A3 (en) | 1972-05-20 |
NL138921B (en) | 1973-05-15 |
GB1251695A (en) | 1971-10-27 |
DE1906551A1 (en) | 1969-08-21 |
NO128958B (en) | 1974-02-04 |
CS155198B2 (en) | 1974-05-30 |
FI50789C (en) | 1976-07-12 |
DK125020B (en) | 1972-12-18 |
BE728221A (en) | 1969-08-11 |
IL31594A0 (en) | 1969-04-30 |
IE32961L (en) | 1969-08-16 |
OA03885A (en) | 1975-08-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DD148050A5 (en) | PROCESS FOR THE PREPARATION OF NEW N-ARYL-BZW.BENZIMIDAZOLIONE | |
Wallingford et al. | X-Ray Contrast Media. I. Iodinated Acylaminobenzoic Acids1 | |
DE1445591A1 (en) | Process for the preparation of derivatives of 7-oxy-2-oxo-1,2-dihydroquinoline | |
DE2057840C3 (en) | Process for the production of indole derivatives | |
DE1906551B2 (en) | 2-alkoxy-3,5-dihalophenyl dialkylaminoalkyl ethers | |
Martin | Hydroxymethylphenols | |
DE1906551C3 (en) | 2-alkoxy-3,5-dihalophenyl dialkylaminoalkyl ether | |
DE1055007B (en) | Process for the preparation of 3-aminothiophene-2-carboxylic acid esters and the corresponding free carboxylic acids | |
DE1695835C3 (en) | 2-Benzyloxybenzamides, medicaments containing them and processes for their preparation | |
DE2252323C3 (en) | 3,6-Dialkyl-23-dihydro-2,9-dioxo-6H, 9H-thiazolo [5,4-fj quinoline-e-carbonyl derivatives, processes for their preparation and their use as bactericides | |
DE701901C (en) | Process for the preparation of thioformamide compounds | |
DE2202486B2 (en) | Process for the preparation of derivatives of 10,11-dihydro-dibenzo [bfl azepinon-10 | |
DE917424C (en) | Process for the preparation of N-acetyl-propargyl-arylamines and their p-position substitution products | |
AT336592B (en) | PROCESS FOR PREPARING NEW 3- (4- BIPHENYLYL) BUTTER ACIDS, THEIR ESTERS, AMIDES AND SALT | |
US2250006A (en) | Anesthetic compounds | |
AT246747B (en) | Process for the preparation of an L-lyxopyranosyl halide | |
DE2513952C2 (en) | PROCESS FOR THE PRODUCTION OF MONOCHLOROBENZOIC ACIDS | |
DE1939697C3 (en) | Amino alcohol esters and agents containing them | |
DE611692C (en) | Process for the preparation of cyclically disubstituted tetrazoles | |
AT163603B (en) | Process for the preparation of new p-aminobenzenesulfonacylamides | |
DE1055538B (en) | Process for the preparation of basic substituted derivatives of 4-aza-phenthiazines | |
AT206898B (en) | Process for the preparation of new thioxanthene derivatives | |
AT228205B (en) | Process for the preparation of basic phenothiazine derivatives which are substituted in the 3-position by a monovalent sulfur function | |
AT218509B (en) | Process for the production of basic substituted carbinols, and of their sterically uniform racemates and their optically active components and / or their acid addition salts | |
AT225181B (en) | Process for the preparation of new phenylalanine derivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C3 | Grant after two publication steps (3rd publication) | ||
E77 | Valid patent as to the heymanns-index 1977 |